Multivariate analysis of antibody induction therapy and their associated outcomes in live donor kidney transplantation in the recent era

Clinical Transplantation

Volumn 26, Issue 2, 2012, Pages 351-358

  Emami, Sina ^a   Huang, Edmund ^a   Kuo, Hung Tien ^a,b   Kamgar, Mohammad ^a   Bunnapradist, Suphamai ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute rejection; Antibody induction; Graft survival; Interleukin 2 receptor antagonist; Kidney transplantation; Thymoglobulin

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; YOUNG ADULT;

EID: 84859858393     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01517.x     Document Type: Article

References (19)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004: 4: 378.
2. 2009 OPTN/SRTR Annual Report 1999-2008. HHS/HRSA/HSB/DOT.
3. Knoll G. Trends in kidney transplantation over the past decade. Drugs 2008: 68(Suppl 1): 3.
4. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998: 128: 817.
5. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004: 77: 166.
6. Tarantino A. Why should we implement living donation in renal transplantation? Clin Nephrol 2000: 53(suppl): 55.
7. Brennan DC, Flavin K, Lowell JA et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999: 67: 1011.
8. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997: 350: 1193.
9. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999: 67: 276.
10. Ponticelli C, Yussim A, Cambi V et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001: 72: 1261.
11. Bunnapradist S, Hong A, Lee B, Takemoto SK. Multivariate analysis of the effectiveness of using antibody induction therapy according to the degree of HLA mismatches. Transplant Proc 2005: 37: 886.
12. Sheashaa HA, Bakr MA, Ismail AM, Mahmoud KM, Sobh MA, Ghoneim MA. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 2008: 12: 376.
13. Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: technology emulating biology. Immunol Res 2004: 29: 41.
14. Zeevi A, Girnita A, Duquesnoy R. HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation. Immunol Res 2006: 36: 255.
15. Lee PC, Ozawa M, Hung CJ, Lin YJ, Chang SS, Chou TC. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Transplant Proc 2009: 41: 95.
16. Gralla J, Wiseman AC. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. Transplantation 2010: 90: 639.
17. Lim WH, Chadban SJ, Campbell S, Dent H, Russ GR, McDonald SP. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients. Nephrology (Carlton) 2010: 15: 368.
18. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008: 248: 564.
19. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. Clin Transplant 2010: 24: 73.